| Oct 3 |
Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic
|
| Sep 24 |
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
|
| Sep 16 |
Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues
|
| Sep 12 |
FDA AdComm to discuss IceCure's ProSense on Nov. 7
|
| Sep 12 |
IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024
|
| Sep 4 |
IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences
|
| Aug 28 |
USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies
|
| Aug 20 |
IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript
|
| Aug 20 |
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 20 |
IceCure Medical GAAP EPS of -$0.14 misses by $0.07, revenue of $1.75M beats by $0.82M
|
